was tirzepatide taken off the market Compounders protest as FDA removes shortage list FDA Grants Tirzepatide a New

Incretin Mimetics All of these medications are part of the class of drugs referred to as incretin mimetics

Research shows GLP-1 therapy improves fasting glucose, reduces A1C, and decreases cardiovascular event risk in individuals with type 2 diabetes regardless of initial weight status

Side Effects Both medications come with potential side effects: Semaglutide: Nausea and vomiting Diarrhea or constipation Low blood sugar (hypoglycemia) Topiramate: Dizziness and fatigue Numbness or tingling in the extremities Mood changes or difficulty concentrating While side effects may vary from person to person, they often diminish over time as the body adjusts to the medication

Furthermore, a balanced diet and awareness of alcohol may influence the medications effectiveness

That works out to approximately $133 per month for the initial subscription period